PVLA
PALVELLA THERAPEUTICS, INC.
+3.13 (+2.07%)154.56USD66.2K成交股數2.2B市值–本益比(近四季)532.0股價營收比+184.8%營收年增(近四季)2026-11-11下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 2.0M+185% | 1.1M+43% | 520K | 628K | 690K+1202% | 752K-42% | 0.00-100% | 0.00-100% | 53K | 1.3M | 19.5M | 20.1M |
| 營業成本 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 毛利率 | – | – | – | – | – | – | – | – | – | – | – | – |
| 研發費用 | 12.5M | 9.3M | 7.1M | 6.5M | 5.1M | 4.1M | 3.2M | 1.4M | 984K | −28.6M | 9.6M | 14.3M |
| 銷售管理費用 | 8.9M | 5.5M | 4.2M | 3.6M | 4.1M | 3.8M | 1.9M | 1.5M | 775K | −11.5M | 6.8M | 3.7M |
| 營業利益 | −21.4M+131% | −14.9M+89% | −11.3M+123% | −10.2M+250% | −9.3M+426% | −7.9M-159% | −5.1M-57% | −2.9M-241% | −1.8M | 13.4M | −11.8M | 2.1M |
| 營業利益率 | -1,089.3% | -1,384.4% | -2,173.8% | -1,620.5% | -1,340.6% | -1,046.7% | – | – | -3,318.9% | 1,030.5% | -60.5% | 10.3% |
| 稅後淨利 | −21.9M+131% | −15.8M+93% | −12.7M+88% | −11.3M+172% | −9.5M+273% | −8.2M-121% | −6.8M-37% | −4.2M-205% | −2.5M | 38.7M | −10.8M | 4.0M |
| 淨利率 | -1,113.0% | -1,469.4% | -2,445.0% | -1,806.5% | -1,372.6% | -1,088.4% | – | – | -4,784.9% | 2,975.4% | -55.1% | 19.8% |
| 稀釋 EPS | -1.52+77% | -1.20+62% | -1.08-73% | -1.03-58% | -0.86-44% | -0.74 | -3.94-55% | -2.47-168% | -1.54 | – | -8.70 | 3.62 |
| 稀釋股數 | 14.4M | 13.1M | 11.3M | 11.1M | 11.1M | 11.0M | 1.8M | 1.8M | 1.8M | 1.8M | 1.2M | 1.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 188M | 206M | 58.0M | 63.6M | 70.4M | 75.6M | 19.4M | 19.7M | 19.1M | 7.4M | 32.9M | 44.9M |
| 應收帳款 | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 373K | 1.5M | 1.8M | 0.00 | 1.0M | 952K |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 254M | 264M | 59.6M | 66.9M | 73.7M | 79.4M | 20.5M | 25.1M | 29.5M | 7.5M | 59.4M | 87.5M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 36.6M | 31.4M | 31.6M | 28.3M | 26.0M | 23.9M | – | – | – | 11.4M | 28.9M | 47.0M |
| 股東權益 | 217M | 232M | 28.0M | 38.7M | 47.8M | 55.6M | −87.4M | −80.8M | −76.9M | −74.5M | 30.5M | 40.5M |
| 負債比 | 14.5% | 11.9% | 53.0% | 42.2% | 35.2% | 30.0% | – | – | – | 151.4% | 48.6% | 53.7% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −10.9M+61% | – | – | – | −6.8M | – | – | −1.1M | – | – | – |
| 資本支出 | – | – | – | – | – | – | – | – | 0.00 | – | – | – |
| 自由現金流 | – | – | – | – | – | – | – | – | −1.1M | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | −30K | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -2,079.2% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 2.6M | +303.4% | −41.7M | -1,610.6% | -3.71 | – |
| FY2024 | 642K | -98.5% | −17.4M | -2,715.6% | -7.83 | – |
| FY2023 | 42.8M | +65.3% | 18.7M | 43.7% | 2.17 | −13.9M |
| FY2022 | 25.9M | -17.6% | −33.3M | -128.5% | – | −61.0M |
| FY2021 | 31.4M | +7.1% | −45.7M | -145.6% | -0.71 | −8.6M |
| FY2020 | 29.3M | -32.8% | −37.2M | -127.0% | -0.68 | −48.6M |
| FY2019 | 43.6M | +60.2% | −25.5M | -58.4% | -0.56 | −54.9M |
| FY2018 | 27.2M | – | −26.8M | -98.2% | -0.50 | −2.8M |